Drugs / 162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05310487 | Sep 2022 → Oct 2023 | chronic hepatitis B virus infection | Yangshengtang Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05310487 ↗ |
| Modality | Monoclonal antibody | “novel neutralizing antibody targeting HBsAg” NCT05310487 ↗ |